Yifei Sanjie Formula or Placebo With Anlotinib as Second-Line or Above Treatment for Metastatic Non-Small-Cell Lung Cancer: Study Protocol for a Double-Blind, Placebo-Controlled Randomized Pilot Study

Yifei Sanjie Formula or Placebo With Anlotinib as Second-Line or Above Treatment for Metastatic Non-Small-Cell Lung Cancer: Study Protocol for a Double-Blind, Placebo-Controlled Randomized Pilot Study

Background: Anlotinib is used as a third-line treatment for advanced non-small-cell lung cancer (NSCLC), but has limited clinical benefits and several side effects, such as diarrhea and acneiform skin rash. Traditional Chinese Medicine (TCM) is commonly used to treat cancers in China. Chinese herbal...

Full description

Bibliographic Details
Main Authors: Wenmin Chen MM, Jietao Lin MD, Ting Yang MM, Ze xin Zhang MM, Lanting Tao MD, Zhiwei Xiao MD, Hanrui Chen MM, Xiangjun Qi MM, Lingling Sun MD, Yang Cao MD, Lizhu Lin MD
Format: Article
Language:English
Published: SAGE Publishing 2023-01-01
Series:Integrative Cancer Therapies
Online Access:https://doi.org/10.1177/15347354221151147

Internet

https://doi.org/10.1177/15347354221151147

Similar Items